Literature DB >> 1287619

Ascertaining how much compliance is enough with outpatient antibiotic regimens.

J Urquhart1.   

Abstract

Compliance with outpatient antibiotic regimens can now be measured by electronically monitoring the time history of dosing. This new approach reveals that many patients comply only partially with prescribed regimens in randomized, controlled, outpatient trials. Omitted or delayed doses and early cessation of dosing are commonly observed. Partial compliance converts a fixed-dose trial into a set of natural experiments in dose ranging, presenting a variety of patterns of dose timing that can be correlated with clinical outcomes for an estimate of minimum compliance needed for satisfactory outcome. Reliable measures indicate little difference in compliance between once- and twice-daily regimens, but considerably higher rates of omitted doses with three-times-daily or four-times-daily dosing. A key practical issue is to ensure continuity of drug action in the face of the most common compliance errors. Continuity of action is more likely when the prescribed interval between doses is considerably shorter, preferably half or less, than the drug's duration of action, allowing doses occasionally to be delayed or omitted without a gap in drug action. Thus, a twice-daily regimen may be expected to maintain crucial continuity of drug action better than a once-daily regimen, even if a few more doses are missed. Errors to avoid in compliance with outpatient antibiotic regimens are prolonged intervals between doses and early cessation of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287619

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  16 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.

Authors:  Joy M Schmitz; Shelly L Sayre; Angela L Stotts; Jennifer Rothfleisch; Marc E Mooney
Journal:  J Behav Med       Date:  2005-04

Review 3.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 4.  The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal.

Authors:  T F Lüscher; F Cosentino
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

5.  Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children.

Authors:  U Behre; H M Burow; P Quinn; F Cree; H E Harrison
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

Review 6.  Pharmacokinetics as an aid to optimising compliance with medications.

Authors:  P Rudd; L Lenert
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 7.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

8.  Assessment of Markov-dependent stochastic models for drug administration compliance.

Authors:  Diane Wong; Reshma Modi; Murali Ramanathan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Compliance of amblyopic patients with occlusion therapy: A pilot study.

Authors:  Sana Al-Zuhaibi; Iman Al-Harthi; Pascale Cooymans; Aisha Al-Busaidi; Yahya Al-Farsi; Anuradha Ganesh
Journal:  Oman J Ophthalmol       Date:  2009-05

10.  Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group.

Authors:  J M Detry; P Block; G De Backer; J P Degaute
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.